Kelly Hardes

871 total citations · 1 hit paper
18 papers, 643 citations indexed

About

Kelly Hardes is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Kelly Hardes has authored 18 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Pharmacology. Recurrent topics in Kelly Hardes's work include Asthma and respiratory diseases (10 papers), Inhalation and Respiratory Drug Delivery (5 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Kelly Hardes is often cited by papers focused on Asthma and respiratory diseases (10 papers), Inhalation and Respiratory Drug Delivery (5 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Kelly Hardes collaborates with scholars based in United Kingdom, United States and Germany. Kelly Hardes's co-authors include Andrew I. Bayliffe, William Powley, David A. Lipson, Aili L. Lazaar, Jason D. Christie, Tracey J. Wright, Germain Poirier, Brian Zeno, Akram Khan and David Fairman and has published in prestigious journals such as Critical Care Medicine, European Respiratory Journal and Critical Care.

In The Last Decade

Kelly Hardes

18 papers receiving 635 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

2017 452 citations Akram Khan, Brian Zeno et al. Critical Care profile →

Peers

Kelly Hardes

PRM

PHYSI

NEURO

CCM

Tracey J. Wright United Kingdom

William Powley United Kingdom

Servet Kayhan Türkiye

Ramin Tolouian United States

José Luís Izquierdo Spain

Brian Zeno United States

Stephany Beyerstedt Brazil

Masoud Nouri‐Vaskeh Iran

Guyi Wang China

Tracey J. Wright United Kingdom

Kelly Hardes

361 ×1.0

141 ×0.9

PRM

116 ×1.0

PHYSI

116 ×1.0

NEURO

97 ×1.0

CCM

Citations per year, relative to Kelly Hardes Kelly Hardes (= 1×) peers Tracey J. Wright

Countries citing papers authored by Kelly Hardes

Since Specialization

Citations

This map shows the geographic impact of Kelly Hardes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly Hardes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly Hardes more than expected).

Fields of papers citing papers by Kelly Hardes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly Hardes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly Hardes. The network helps show where Kelly Hardes may publish in the future.

Co-authorship network of co-authors of Kelly Hardes

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly Hardes. A scholar is included among the top collaborators of Kelly Hardes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly Hardes. Kelly Hardes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Singh, Dave, Rainard Fuhr, Kelly Hardes, et al.. (2021). A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma. British Journal of Clinical Pharmacology. 88(2). 702–712. 34 indexed citations

Bayliffe, Andrew I., Daniel F. McAuley, Joyce Yeung, et al.. (2020). A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study. European Journal of Anaesthesiology. 37(11). 1014–1024. 7 indexed citations

Khan, Akram, Brian Zeno, Timothy E. Albertson, et al.. (2017). A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care. 21(1). 234–234. 452 indexed citations breakdown →

Schmidt, Tim, Disala Fernando, Kelly Hardes, et al.. (2016). Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies. Inflammation Research. 65(5). 389–404. 15 indexed citations

Dölle, Sabine, et al.. (2015). Clinical Efficacy and Tolerability of a Novel Selective Corticosteroid in Atopic Dermatitis - Two Randomised Controlled Trials. Skin Pharmacology and Physiology. 28(3). 159–166. 9 indexed citations

Christie, Jason D., Steven N. Vaslef, Philip K.‐Y. Chang, et al.. (2015). A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome. Critical Care Medicine. 43(9). 1859–1869. 29 indexed citations

Mehta, Rashmi, Kelly Hardes, Dennis Kelleher, et al.. (2014). Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study. Clinical Therapeutics. 36(7). 1016–1027.e2. 10 indexed citations

Mehta, Rashmi, Kelly Hardes, Noushin Brealey, et al.. (2014). Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. International Journal of COPD. 10. 15–15. 10 indexed citations

Bareille, Philippe, Kelly Hardes, & Alison Donald. (2013). Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial. Journal of Asthma. 50(10). 1077–1082. 11 indexed citations

10.

Mehta, Rashmi, Kelly Hardes, Dennis Kelleher, et al.. (2013). Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). 42. 3641. 3 indexed citations

11.

Cahn, Anthony, Ruth Tal‐Singer, Isabelle Pouliquen, et al.. (2013). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies. Clinical Drug Investigation. 33(7). 477–488. 21 indexed citations

12.

Kelleher, Dennis, Kelly Hardes, Noushin Brealey, et al.. (2013). Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). 42. 4148. 4 indexed citations

13.

Allen, Ann, Philippe Bareille, Kelly Hardes, & Jonathan Robertson. (2013). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies. Current Drug Therapy. 8(2). 76–85. 2 indexed citations

14.

Bareille, Philippe, Kelly Hardes, Jonathan Robertson, Angela Davis, & Ann Allen. (2013). Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial. Current Drug Therapy. 8(2). 69–75. 1 indexed citations

15.

Bareille, Philippe, Ann Allen, Kelly Hardes, & Alison Donald. (2013). Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study. Current Drug Therapy. 8(3). 155–163. 2 indexed citations

16.

Allen, Ann, Angela Davis, Kelly Hardes, Lee Tombs, & Rodger Kempsford. (2012). Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination. Clinical Therapeutics. 34(12). 2316–2332. 17 indexed citations

17.

Kelleher, Dennis, Andrew Preece, Rashmi Mehta, et al.. (2011). Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD). European Respiratory Journal. 38(Suppl 55). p834–p834. 4 indexed citations

18.

Mehta, Rashmi, Kelly Hardes, Anthony Cahn, et al.. (2011). Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults. 38. 3972. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact